Evaluation of Periprocedural Safety and Efficacy of Dabigatran, Rivaroxaban, Apixaban and Edoxaban During Catheter Ablation for Atrial Fibrillation

被引：0
|
作者：
Tohoku, Shota
Hiroshima, Kenichi
Nagashima, Michio
Morita, Junji
Iseda, Takahiro
Ando, Kengo
Ando, Kenji
机构：
来源：
CIRCULATION | 2016年 / 134卷
关键词：
Ablation; Anticoagulants; Dabigatran; Rivoraxaban; Apixaban;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
16578
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon
    Tscholl, Verena
    Lsharaf, Abdullah Khaled-A.
    Lin, Tina
    Bellmann, Barbara
    Nagel, Patrick
    Lenz, Klaus
    Landmesser, Ulf
    Roser, Mattias
    Rillig, Andreas
    CLINICAL CARDIOLOGY, 2017, 40 (11) : 1095 - 1099
  • [22] Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation
    Bassiouny, Mohamed
    Saliba, Walid
    Rickard, John
    Shao, Mingyuan
    Sey, Albert
    Diab, Mariam
    Martin, David O.
    Hussein, Ayman
    Khoury, Maurice
    Abi-Saleh, Bernard
    Alam, Samir
    Sengupta, Jay
    Borek, P. Peter
    Baranowski, Bryan
    Niebauer, Mark
    Callahan, Thomas
    Varma, Niraj
    Chung, Mina
    Tchou, Patrick J.
    Kanj, Mohamed
    Dresing, Thomas
    Lindsay, Bruce D.
    Wazni, Oussama
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2013, 6 (03): : 460 - 466
  • [23] Safety and efficacy of uninterrupted periprocedural rivaroxaban in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of 1,362 patients
    Garg, Jalaj
    Chaudhary, Rahul
    Krishnamoorthy, Parasuram
    Shah, Neeraj
    Natale, Andrea
    Bozorgnia, Babak
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 203 : 906 - 908
  • [24] Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature
    Hohnloser, Stefan H.
    Camm, A. John
    EUROPACE, 2013, 15 (10): : 1407 - 1411
  • [25] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
    Wisloff, Torbjorn
    Hagen, Gunhild
    Klemp, Marianne
    PHARMACOECONOMICS, 2014, 32 (06) : 601 - 612
  • [26] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
    Torbjørn Wisløff
    Gunhild Hagen
    Marianne Klemp
    PharmacoEconomics, 2014, 32 : 601 - 612
  • [27] Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis
    Harenberg, J.
    Marx, S.
    Diener, H. -C.
    Lip, G. Y. H.
    Marder, V. J.
    Wehling, M.
    Weiss, C.
    INTERNATIONAL ANGIOLOGY, 2012, 31 (04) : 330 - 339
  • [28] Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation
    Hernandez, Inmaculada
    Zhang, Yuting
    Saba, Samir
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (10): : 1813 - 1819
  • [29] Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
    Rutherford, Ole-Christian W.
    Jonasson, Christian
    Ghanima, Waleed
    Soderdahl, Fabian
    Halvorsen, Sigrun
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (02) : 75 - 85
  • [30] Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation (vol 175, pg 1515, 2022)
    Lau, W. C. Y.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : 144 - 144
12345